Stage III Kidney Wilms Tumor Clinical Trial
Official title:
A Genome-Wide Association Study in Wilms Tumor
Verified date | July 2016 |
Source | Children's Oncology Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Observational |
This clinical trial studies gene analysis in studying susceptibility to Wilms tumor. Finding genetic markers for Wilms tumor may help identify patients who are at risk of relapse.
Status | Completed |
Enrollment | 1 |
Est. completion date | November 2009 |
Est. primary completion date | November 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - 3000 samples from the 1958 Birth Cohort (58C) and 3000 from the UK Blood Service control series (NBS) |
N/A
Country | Name | City | State |
---|---|---|---|
United States | Childrens Oncology Group | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Children's Oncology Group | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequencies between cases and controls at each SNP | Compared using the Cochran Armitage trend test (1-df). The data will be analyzed individually for the UK/US study populations and combined using a Mantel-Haenszel analysis adjusting for study group, and related methods which allow for different effects in each population (for confirmed loci, we will compare effects across populations). | Baseline | No |
Primary | Frequency of maternal and paternal allelic transmission for risk alleles | Compared using a chi-squared test. | Baseline | No |
Primary | Genetic variation on sub-phenotypes such as age at diagnosis, unilateral or bilateral disease, sex, and ethnicity | Baseline | No | |
Primary | Interactions between genetic variation and treatment success or prognosis | Baseline | No | |
Primary | Interactions between germline genetic variation and tumor phenotypes | Baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04322318 -
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
|
Phase 2 | |
Active, not recruiting |
NCT00352534 -
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
|
Phase 3 | |
Not yet recruiting |
NCT06401330 -
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
|
Phase 3 | |
Active, not recruiting |
NCT00945009 -
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
|
Phase 3 | |
Active, not recruiting |
NCT00379340 -
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
|
Phase 3 |